Merck announced that the US District Court for the District of New Jersey ruled in favor of the company and found that Merck correctly calculated the Patent Term Extension period for the primary patent related to BRIDION® (sugammadex). Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
Today’s ruling from the U.S. District Court for the District of New Jersey affirms and validates Merck’s U.S. patent protection for BRIDION through at least January 2026.
“Merck’s science and technology was used to develop and launch BRIDION, and we’re pleased that the Court recognized the validity of our full patent extension period granted by the Patent Office,” said Jennifer Zachary, executive vice president and general counsel, Merck. “Innovations like these contribute to a broader ecosystem that allows us to continue investing in research and development to bring important new therapies and vaccines forward to the patients who need them.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!